Drug intelligence / Profile preview

TXA6101

Development stage: Preclinical
Lead developer: TAXIS Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

TXA6101 is a small molecule inhibitor of the bacterial protein FtsZ, currently in lead optimization by TAXIS Pharmaceuticals for the treatment of *Clostridioides difficile* infection (CDI). FtsZ is a tubulin-like protein essential for bacterial cell division, forming the 'Z-ring' at the septum. By targeting FtsZ, TXA6101 disrupts the cell division process, leading to bacterial cell death. This mechanism is distinct from traditional antibiotics, potentially offering a new approach to managing CDI and reducing recurrence.

Targets

FtsZ (Filamentous temperature-sensitive protein Z)

Beyond the preview

Go deeper on TXA6101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TXA6101.

Explore the full profile